Literature DB >> 33735282

Different mechanisms of oxygenator failure and high plasma von Willebrand factor antigen influence success and survival of venovenous extracorporeal membrane oxygenation.

Tamara Steiger1, Alois Philipp1, Karl-Anton Hiller2, Thomas Müller3, Matthias Lubnow3, Karla Lehle1.   

Abstract

OBJECTIVE: Failure of membrane oxygenator (MO) function of venovenous extracorporeal membrane oxygenators (VV ECMO) remains problematic. The development of device-induced coagulation disorder (COD) or worsened gas transfer (WGT) necessitates a system exchange. The aim was to correlate von Willebrand factor antigen (vWF:Ag) with the predisposition to MO failure and mortality.
METHODS: Laboratory parameters (inflammation, coagulation) and ECMO-related data from 31 VV ECMO patients were analyzed before and after the first MO exchange. Study groups were identified according to the exchange reasons (COD, WGT) and the extent of vWF:Ag (low, ≤425%; high, >425%).
RESULTS: vWF:Ag remained unchanged after system exchange. High vWF:Ag was associated with systemic endothelial activation of older and obese patients with elevated SOFA score, increased norepinephrine and higher requirement of continuous renal replacement therapy without an effect on MO runtime and mortality. Including the mechanism of MO failure (COD, WGT), various patient group emerged. COD/low vWF:Ag summarized younger and less critically ill patients that benefit mainly from ECMO by a significant improvement of their inflammatory and coagulation status (CRP, D-dimers, fibrinogen) and highest survival rate (91%). Instead, WGT/high vWF:Ag presented older and more obese patients with a two-digit SOFA score, highest norepinephrine, and aggravated gas transfer. They benefited temporarily from system exchange but with worst survival (33%).
CONCLUSIONS: vWF:Ag levels alone cannot predict early MO failure and outcome in VV ECMO patients. Probably, the mechanism of clotting disorder in combination with the vWF:Ag level seems to be essential for clot formation within the MO. In addition, vWF:Ag levels allows the identification different patient populations In particular, WGT/high vWF:Ag represented a critically ill population with higher ECMO-associated mortality.

Entities:  

Year:  2021        PMID: 33735282      PMCID: PMC7971568          DOI: 10.1371/journal.pone.0248645

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  28 in total

Review 1.  Contemporary extracorporeal membrane oxygenation for adult respiratory failure: life support in the new era.

Authors:  Graeme MacLaren; Alain Combes; Robert H Bartlett
Journal:  Intensive Care Med       Date:  2011-12-07       Impact factor: 17.440

Review 2.  Extracorporeal membrane oxygenation, an anesthesiologist's perspective: physiology and principles. Part 1.

Authors:  Sandeep Chauhan; S Subin
Journal:  Ann Card Anaesth       Date:  2011 Sep-Dec

3.  Extracorporeal membrane oxygenation induces short-term loss of high-molecular-weight von Willebrand factor multimers.

Authors:  Helmuth Tauber; Helmut Ott; Werner Streif; Guenter Weigel; Lorin Loacker; Josef Fritz; Anneliese Heinz; Corinna Velik-Salchner
Journal:  Anesth Analg       Date:  2015-04       Impact factor: 5.108

4.  von Willebrand factor is an acute phase reactant in man.

Authors:  B E Pottinger; R C Read; E M Paleolog; P G Higgins; J D Pearson
Journal:  Thromb Res       Date:  1989-02-15       Impact factor: 3.944

5.  Acquired von Willebrand syndrome in patients with extracorporeal life support (ECLS).

Authors:  Claudia Heilmann; Ulrich Geisen; Friedhelm Beyersdorf; Lea Nakamura; Christoph Benk; Georg Trummer; Michael Berchtold-Herz; Christian Schlensak; Barbara Zieger
Journal:  Intensive Care Med       Date:  2011-10-01       Impact factor: 17.440

Review 6.  Oxygenator performance and artificial-native lung interaction.

Authors:  Francesco Epis; Mirko Belliato
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

Review 7.  The various states of von Willebrand factor and their function in physiology and pathophysiology.

Authors:  Volker Huck; Matthias F Schneider; Christian Gorzelanny; Stefan W Schneider
Journal:  Thromb Haemost       Date:  2014-02-27       Impact factor: 5.249

8.  Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor.

Authors:  B Savage; E Saldívar; Z M Ruggeri
Journal:  Cell       Date:  1996-01-26       Impact factor: 41.582

9.  Variations in the ratio between von Willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure.

Authors:  Ralf A Claus; Clemens L Bockmeyer; Ulrich Budde; Karim Kentouche; Maik Sossdorf; Thomas Hilberg; Reinhart Schneppenheim; Konrad Reinhart; Michael Bauer; Frank M Brunkhorst; Wolfgang Lösche
Journal:  Thromb Haemost       Date:  2009-02       Impact factor: 5.249

10.  Margination and stretching of von Willebrand factor in the blood stream enable adhesion.

Authors:  Kathrin Rack; Volker Huck; Masoud Hoore; Dmitry A Fedosov; Stefan W Schneider; Gerhard Gompper
Journal:  Sci Rep       Date:  2017-10-27       Impact factor: 4.379

View more
  1 in total

Review 1.  Thrombosis and coagulopathy in COVID-19 patients rceiving ECMO: A narrative review of current literature.

Authors:  Hakeem Yusuff; Vasileios Zochios; Daniel Brodie
Journal:  J Cardiothorac Vasc Anesth       Date:  2022-03-31       Impact factor: 2.894

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.